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Post hoc analysesThe peak age at onset of Lennox–Gastaut syndrome (LGS) is between 3 and 5 years. Patients with LGS frequently
experiencemultiple types of treatment-refractory seizures and require lifelong therapywith several antiepileptic
drugs. Here, post hoc analyses of clinical trials (phase III trial OV-1012 and open-label extension trial OV-1004)
provide short- and long-term efﬁcacy and safety data of adjunctive clobazam in patients with LGS stratiﬁed by
age at baseline (≥2 to b12 years, ≥12 to b17 years, and ≥17 years). In OV-1012, 301 patients were screened,
238 were randomized, 217 comprised the modiﬁed intention-to-treat population, and 177 completed
the study. A total of 267/306 patients (61 of 68 from phase II trial OV-1002 and 206 of 238 from phase III trial
OV-1012) entered the open-label extension trial. Demographics and clinical characteristicswere similar between
different age groups in OV-1012 and OV-1004. No differences in efﬁcacy or adverse events were observed across
age groups in OV-1012 and OV-1004. The results of these post hoc analyses show that adjunctive clobazam over
the short and longterm was similarly effective and well-tolerated in both pediatric and adult patients with LGS.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Lennox–Gastaut syndrome (LGS) is a severe type of epilepsy that has a
peak age at onset between 3 and 5 years [1,2]. Patients with LGS typically
experiencemultiple seizure types, predominantly tonic and atonic seizures
that can cause the patient to suddenly fall (“drop seizures”). These patients
oftenhave seizures that are refractory to treatmentwith antiepileptic drugs
(AEDs), andmany require lifelong AED polytherapy tomanage theirmulti-
ple seizure types [1,3–6]. As patients with LGS age and transition from pe-
diatric to adult care, it is clinically important to understand the efﬁcacy and
safety of AEDs across the age spectrum [7].
Approved by the U.S. Food and Drug Administration (FDA) in October
2011, the 1,5-benzodiazepine clobazam is indicated for the adjunctive
treatment of seizures associated with LGS in patients 2 years and older.partment of Pediatrics, Baylor
, 315 N. San Saba Street, Suite
; fax: +1 210 704 4527.
. This is an open access article underThe results from two randomized controlled studies (phase II OV-1002
[NCT00162981] [8] and phase III OV-1012 [NCT00518713], also known as
the CONTAIN trial [9]) demonstrated that clobazam was efﬁcacious and
well-tolerated for the treatment of LGS. Patients from the lead-in studies
were eligible to enroll in OV-1004 (NCT01160770), an open-label exten-
sion (OLE) trial [10]. The results from the up to 6-year OLE study showed
that stable dosages of adjunctive clobazam improved seizure control, with
some patients achieving and maintaining long-term seizure freedom.
To evaluate short- and long-term clobazam efﬁcacy and safety across
different ages, we conducted post hoc analyses of patient data grouped
by those who were ≥2 to b12 years, ≥12 to b17 years, and ≥17 years
of age at baseline.2. Materials and methods
Data for these post hoc analyseswere derived fromboth the phase III
trial OV-1012 (short-term results) [9] andOLE trial OV-1004 (long-term
results) [10]. Detailed methodologies for both studies have been
published and are summarized below.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
OV-1012 (A) and OV-1004 (B) patient demographics and baseline characteristics by age groups (safety populations).
A) OV-1012
≥2 to b12 years (children) ≥12 to b17 years (adolescents) ≥17 years (adults)
Placebo (N = 36) Clobazam (N = 110) Placebo (N = 10) Clobazam (N = 30) Placebo (N = 13) Clobazam (N = 39)
Age, years
Mean (SD) 7.7 (2.58) 6.8 (2.83) 14.2 (1.36) 14.2 (1.49) 26.6 (10.09) 26.1 (7.70)
Median 7.4 7.1 14.4 13.9 24.1 24.1
Male, n (%) 21 (58.3) 66 (60.0) 8 (80.0) 16 (53.3) 9 (69.2) 24 (61.5)
Weekly drop-seizure rate at baseline
Mean (SD) 108.1 (150.94) 95.2 (154.96) 141.1 (287.56) 113.5 (241.27) 25.8 (28.71) 26.7 (30.51)
Median 57.3 39.5 25.5 21.3 9.3 18.4
Range 2–744 2–994 6–920 3–1077 3–87 2–170
Time since LGS diagnosis, years
Mean (SD) 2.9 (2.69) 2.7 (2.85) 8.9 (3.45) 7.9 (3.21) 22.2 (10.96) 21.5 (8.33)
Prior number of AEDs, n (%)
0 3 (8.3) 7 (6.4) 0 1 (3.3) 0 1 (2.6)
1 3 (8.3) 25 (22.7) 2 (20.0) 5 (16.7) 1 (7.7) 5 (12.8)
2 7 (19.4) 17 (15.5) 2 (20.0) 3 (10.0) 0 3 (7.7)
3 4 (11.1) 12 (10.9) 0 3 (10.0) 1 (7.7) 4 (10.3)
≥4 19 (52.8) 49 (44.5) 6 (60.0) 18 (60.0) 11 (84.6) 26 (66.7)
B) OV-1004
Children (N = 176) Adolescents (N = 45) Adults (N = 46)
Age, years
Mean (SD) 7.0 (2.65) 14.1 (1.48) 24.6 (8.32)
Median 7.2 13.9 22.0
Male, n (%) 109 (61.9) 28 (62.2) 26 (56.5)
Time since LGS diagnosis, years
Mean (SD) 2.7 (2.47) 7.6 (3.55) 19.4 (9.44)
Prior number of AEDs, n (%)
0 10 (5.7) 1 (2.2) 0
1 20 (11.4) 5 (11.1) 5 (10.9)
2 22 (12.5) 6 (13.3) 2 (4.3)
3 17 (9.7) 3 (6.7) 3 (6.5)
≥4 107 (60.8) 30 (66.7) 36 (78.3)
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Trial OV-1012 was a phase III, multicenter, randomized, double-
blind, placebo-controlled, parallel-group study. Patients eligible to
participate in this trial were between 2 and 60 years of age with a
diagnosis of LGS (onset at b11 years of age), weighing ≥12.5 kg, and
receiving stable dosages of 1 to 3 AEDs (except benzodiazepines) for
≥30 days. A 4-week baseline period, a 3-week titration period, and a
12-week maintenance period comprised the study. During the baseline
period, patients who experienced ≥2 drop seizures were stratiﬁed
by weight (12.5 kg to ≤30 kg and N30 kg) and then randomized to
1 of 3 clobazam treatment groups (low-dosage clobazam: target of
0.25 mg/kg/day [maximum: 10 mg/day], medium-dosage clobazam:
target of 0.5 mg/kg/day [maximum: 20 mg/day], and high-dosage
clobazam: target of 1.0 mg/kg/day [maximum: 40mg/day]) or placebo.
Open-label extension trial OV-1004 enrolled patients who
participated in the phase II study OV-1002 [8] or the phase III study
OV-1012 [9]. Most patients initially received 0.5 mg/kg/day (≤20 mg/
day) of open-label clobazam.Dosageswere then adjusted based on clin-
ical response (efﬁcacy and tolerability), up to a maximum of
2.0 mg/kg/day (80 mg/day); the published mean maximum dosage
for Years 3 through 5 was 1.2 mg/kg/day [10]. Patients outside the
United States did not continue in the study beyond 24 months (per
protocol), resulting in much lower patient numbers for Year 3 and
beyond, independent of efﬁcacy and safety results.Fig. 1. Percentage decreases in average weekly rate of drop (A) and total (B) seizures by
age in OV-1012: children (≥2 to b12 years), adolescents (≥12 to b17 years), and adults
(≥17 years). CLB, clobazam.2.2. Post hoc analyses of efﬁcacy and safety
Patient efﬁcacy and safety data from studies OV-1012 and OV-1004
were evaluated by the following age groups at baseline:≥2 to b12years
(children), ≥12 to b17 years (adolescents), and ≥17 years (adults).
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decrease in weekly drop- and total-seizure (drop and nondrop)
frequency and treatment responders by mean weekly rates (≥50%
and 100%) of drop and total seizures during the maintenance vs. base-
line phases for the modiﬁed intention-to-treat (mITT) population. For
study OV-1004, efﬁcacy outcomes included the median percentage
decrease in the average weekly rate of drop and total seizures and
responder rates for reduction from baseline (≥50% and 100%) in aver-
age weekly rate of drop and total seizures evaluated from baseline to
Years 1 through 3.
Safety outcomes included adverse events (AEs), serious AEs (SAEs),
discontinuations due to AEs, and clinical and laboratory ﬁndings. Safety
data for the overall trial populations have been published [9,10].
2.3. Statistical analyses
The safety population included all patients who received treatment
during either trial. For the OV-1012 analyses, the mITT population
included all randomized patients who had baseline data, ≥1 dose of
studymedication, and≥1 daily seizure measurement during the main-
tenance phase. In OLE study OV-1004, the efﬁcacy analysis set included
all patients with baseline and postbaseline assessments within the
designated year. For the OLE trial, baseline was deﬁned as 1) the last
week of recorded seizures prior to receiving their ﬁrst dose of clobazam
for patients who received placebo in OV-1012 or 2) the last week ofFig. 2. ≥50% and 100% responders by average weekly rate of drop (A) and total (B) seizures by
adults (≥17 years). CLB, clobazam.recorded seizures from the baseline period of the blinded study for
patients who received clobazam in OV-1002 or OV-1012.
3. Results
3.1. Patient demographics and baseline clinical characteristics
In OV-1012, 301 patients were screened and 238 were randomized.
Of these, 217 patients comprised the mITT population, and 177 com-
pleted the study [9]. The safety population included 146 children, 40
adolescents, and 52 adult patients. A total of 267 of 306 eligible patients
from the lead-in trials (OV-1002: 61/68 patients; OV-1012: 206/308
patients) entered, and 188 (70%) completed OLE study OV-1004. A
total of 251 patients had received clobazam for ≥6 months, 229 for
≥1 year, 210 for ≥2 years, 121 for ≥3 years, 54 for ≥4 years, and 44
for ≥5 years [10]. Of the 89 patients who discontinued between Years
2 and 3, 39 were outside the United States and were discontinued per
protocol. The safety population included 176 children, 45 adolescents,
and 46 adult patients. Demographic and baseline characteristics data
for patients in trials OV-1012 and OV-1004 are presented in Table 1.
3.2. Efﬁcacy by age groups
Percentage decreases in drop and total seizures in OV-1012 were
similar across age groups and proportional to clobazam dosage in bothage group in OV-1012: children (≥2 to b12 years), adolescents (≥12 to b17 years), and
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100%) for drop and total seizures by age groups are presented in
Fig. 2. Treatment with medium- and high-dosage clobazam resulted in
numerically ≥50% responder rates than placebo across all age groups.
In the OLE trial, the median seizure decreases were substantial
and sustained in all age groups (Fig. 3). Data for patients who were
≥50% responders or experienced seizure freedom (100% responders)
across the age groups are presented in Fig. 4. The percentages of
patients who experienced a ≥50% response rate and seizure freedom
were sustained for drop and total seizures through Year 3 across all
age groups.3.3. Safety by age group
Adverse events that occurred at ≥10% of clobazam-treated patients
across age groups in OV-1012 are presented in Table 2. A total of 13/110
(12%) and 1/39 (3%) clobazam-treated children and adults, respectively,
experienced an SAE; no adolescent patients experienced an SAE. A total
of 10/110 (9%) clobazam-treated children vs. 1/36 (3%) placebo-treated
children, 7/30 (23%) vs. 0/10 (0%) adolescents, and 8/39 (21%) vs. 1/13
(8%) adults experienced an AE that led to discontinuation from the trial.
In the OLE trial, a similar percentage of patients in each age group
experienced AEs (children: 163/176 [93%], adolescents: 41/45 [91%],
and adult patients: 42/46 [91%]) (Table 3). The incidence rates of SAEs
were 42% for children, 42% for adolescents, and 48% for adults. A totalFig. 3. Percentage decreases in average weekly rate of drop (A) and total (B) seizures by
age group in OV-1004 (OLE): children (≥2 to b12 years), adolescents (≥12 to
b17 years), and adults (≥17 years).of 11 (6%) children and 7 (15%) adults discontinued the OLE trial
because of AEs, of which none occurred in N2 patients.
Six children died during the OLE trial. Fatal AEs were pneumonia
(3 patients), cardiopulmonary arrest (1 patient), the combination of
preexisting seizure increase, atelectasis, and hypoxic respiratory failure
(1 patient), and death of unknown etiology (1 patient). One adolescent
patient died because of pneumonia. A total of three adults died
(1 patient each because of epilepsy; the combination of pneumonia,
acute respiratory distress syndrome [ARDS], and sepsis; and ARDS
and right leg hematoma). The AE of convulsion with an outcome of
death in one child was considered “possibly related” to clobazam by
the investigator; all other deaths were deemed “unlikely related” or
“not related” to clobazam.4. Discussion
These post hoc analyses of the double-blind and OLE trials evaluated
the short- and long-term efﬁcacy and safety of clobazam in children,
adolescents, and adults with a diagnosis of LGS (before 11 years of age).
Analyses of short-term efﬁcacy data from the double-blind trial
showed that clobazam-treated patients achieved similar percentages
of drop- and total-seizure decreases across age groups. Drop- and
total-seizure responder rates were consistent across age groups, espe-
cially for patients in the medium- and high-dosage clobazam treatment
groups. A greater percentage of adolescent and adult patients who
received high-dosage clobazam appear to achieve notable rates of
drop- and total-seizure freedom. Evaluation of long-term efﬁcacy data
from the OLE trial showed that median drop- and total-seizure de-
creases as well as ≥50% and 100% drop- and total-seizure responder
rates were sustained across age groups through Year 3. These data
indicate that adult patients treated with clobazam responded nearly
as well as children, despite presumably having a longer duration of
seizure disorder. Though these short- and long-term efﬁcacy results
are informative, they are only descriptive. Furthermore, the limited
number of adolescent and adult patients prevents substantive statistical
analyses of these data. Finally, although patients from the long-term
trial could have discontinued the study because of lack of efﬁcacy,
only 6%had elected towithdraw,which suggests limited patient enrich-
ment for efﬁcacy [10].
Safety analyses of the short- and long-term trial data across the age
groups were consistent with the overall safety results [9,10]. Pyrexia
occurred more frequently in pediatric patients (b17 years), which is
to be expected, whereas aggression, ataxia, and drooling occurred
more frequently in adolescent and adult patients. Serious AEs were
more frequently reported in children, of which pneumonia and lobar
pneumonia were most common, yet not unexpected. Pediatric patients
discontinued from OV-1012 for lethargy and somnolence, whereas
adult patients discontinued for aggression, ataxia, and insomnia. In the
OLE trial, AEs such as pyrexia, pneumonia, and otitis media were more
commonly reported in children; however, for a trial of this duration,
these AEs were anticipated. The incidences of commonly reported
SAEs were similar across age groups, and no noticeable difference was
observed regarding AEs that led to discontinuation. Overall, these data
suggest that clobazam had a similar tolerability proﬁle for patients
with LGS across age groups.
Although the onset of LGS often occurs in patients between 3 and
5 years of age, unfortunately, most patients do not outgrow their
epileptic encephalopathy even if their EEG characteristics change over
time. Most patients experience lifelong treatment-resistant epilepsy
and intellectual disabilities, and many have behavioral issues such as
aggression [7,11]. These post hoc analyses show that adults with LGS
experienced similar drop- and total-seizure responses following
treatment with clobazam as younger patients. These ﬁndings suggest
that clobazam remains an appropriate treatment option across all
age groups.
Fig. 4.≥50% and 100% responders by average weekly rate of drop (A) and total (B) seizures by age group in OV-1004 (OLE): children (≥2 to b12 years), adolescents (≥12 to b17 years),
and adults (≥17 years).
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Table 2
OV-1012: adverse events reported by ≥10% of clobazam-treated patients: (A) ≥2 to
b12 years (children), (B) ≥12 to b17 years (adolescents), and (C) ≥17 years (adults)
(safety population).
A) Children
AE Placebo (N = 36), n (%) Clobazam (N = 110), n (%)
Any AE 21 (58.3) 88 (80.0)
Somnolence 6 (16.7) 24 (21.8)
URTI 4 (11.1) 21 (19.1)
Pyrexia 2 (5.6) 18 (16.4)Conclusions
Efﬁcacy data analyses from trials OV-1012 [9] and OV-1004 [10] of
patients with LGS treated with adjunctive clobazam demonstrated
similar and sustained efﬁcacy results over the short and long-term in
children (≥2 to b12 years), adolescents (≥12 to b17 years), and adults
(≥17 years). Short- and long-term analyses of safety data did not reveal
unexpected trends by age group. The results of these post hoc analyses
show that adjunctive clobazamwas equally effective andwell-tolerated
across the age spectrum.B) Adolescents
AE Placebo (N = 10), n (%) Clobazam (N = 30), n (%)
Any AE 8 (80.0) 22 (73.3)
Lethargy 0 7 (23.3)
Somnolence 0 7 (23.3)
Aggression 1 (10.0) 3 (10.0)
Ataxia 0 3 (10.0)
Drooling 0 3 (10.0)
Nasopharyngitis 3 (30.0) 3 (10.0)
Pyrexia 0 3 (10.0)
C) Adults
AE Placebo (N = 13), n (%) Clobazam (N = 39), n (%)
Any AE 11 (84.6) 32 (82.1)
Somnolence 1 (7.7) 8 (20.5)
Aggression 2 (15.4) 7 (17.9)
Fatigue 1 (7.7) 5 (12.8)
Sedation 1 (7.7) 5 (12.8)
Ataxia 1 (7.7) 4 (10.3)
Drooling 0 4 (10.3)
Insomnia 0 4 (10.3)
Psychomotor hyperactivity 1 (7.7) 4 (10.3)
AE, adverse event; URTI, upper respiratory tract infection.Acknowledgments
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